Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 14/20 | 0.60 |
| ▸ | HINT1 | P49773 | 1/20 | 0.49 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304362 | 0.87 | TYMP (0.67) | TYMPP2RY12ADORA1 | |
| SCHEMBL19493362 | 0.87 | TYMP (0.67) | TYMPP2RY12ADORA1 | |
| SCHEMBL917680 | 0.87 | TYMP (0.67) | TYMPP2RY12ADORA1 | |
| SCHEMBL8386141 | 0.87 | TYMP (0.67) | TYMPP2RY12ADORA1 | |
| SCHEMBL19493363 | 0.87 | TYMP (0.67) | TYMPP2RY12ADORA1 | |
| SCHEMBL917678 | 0.87 | TYMP (0.67) | TYMPP2RY12ADORA1 | |
| SCHEMBL7529299 | 0.87 | TYMP (0.67) | TYMPP2RY12ADORA1 | |
| SCHEMBL29679722 | 0.87 | TYMP (0.67) | TYMPP2RY12ADORA1 | |
| SCHEMBL7529826 | 0.86 | TYMP (0.66) | TYMPP2RY12ADORA1 | |
| SCHEMBL8613305 | 0.84 | TYMP (0.58) | TYMPADORA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | KANEKA CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009609-A1 | 2'-HYDROXY-PROTECTED RIBONUCLEOSIDE DERIVATIVE AND PRODUCTION METHOD THEREOF | RNASEL, RNASEH1, NUDT1 | TYMP 183/4885HINT1 234/4885P2RY12 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.